



By Carolyn Gretton

▶ PHARMACEUTICAL POOL

Dr. Lawrence **BLOCH**

INFINITY NAMES BUSINESS CHIEF



Lawrence Bloch, M.D., has joined Infinity Pharmaceuticals as executive VP, chief financial officer, and chief business officer. Dr. Bloch is responsible for the company's corporate, financial, and business development strategies and operations.

Dr. Bloch brings to Infinity more than 12 years of experience in building and leading biotech companies, most recently as CEO of NeurAxon. He holds a J.D. from Harvard Law School, an M.D. from Harvard Medical School, and an MBA from Harvard Business School.

Dr. Carlo **DE NOTARISTEFANI**

Aharon (Arik) **YAARI**

NEW GLOBAL OPERATIONS HEAD AT TEVA



Israel-based global pharmaceutical company Teva Pharmaceutical Industries has named Carlo De Notaristefani, Ph.D., president and CEO of global operations. Dr. De Notaristefani has responsibility for Teva's product supply and manufacturing network and ensuring that the company exceeds the highest standards in executing an integrated supply chain operation on a global level.

Recently, Dr. De Notaristefani was president, technical operations and global support functions, for Bristol-Myers Squibb. He received a doctoral degree in chemical engineering from the University of Naples in Italy.

In other moves, Teva veteran Aharon (Arik) Yaari has been appointed executive VP to the company's newly formed community and institutional affairs organization. Mr. Yaari joined Teva in 1981 and most recently served as group VP, Teva Generics Systems. He received an M.A. in economics from the Hebrew University of Jerusalem.

Dr. Ponni **SUBBIAH**

FORMER PFIZER VP JOINS ONEWORLD HEALTH



OneWorld Health (OWH) has named Ponni Subbiah, M.D., global program leader responsible for OWH's drug development portfolio, which is now a program of PATH, an OWH affiliate and international nonprofit organization that transforms global health through innovation. Dr.

Subbiah joins OWH after 15 years with Pfizer, where she most recently served as VP of global access within the emerging markets business unit. She received an M.D. from Madras Medical College in India and an MPH from Johns Hopkins University.

▶ BIOPHARMACEUTICAL POOL

Armando **ANIDO**

NEW CHIEF EXECUTIVE AT NUPATHE



NuPathe, a biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, has named Armando Anido to succeed Jane Hollingsworth as CEO. Mr. Anido has more than 30 years of executive, operational, and commercial leadership experience in the biopharma industry, including a stint as president and CEO of Auxilium Pharmaceuticals.

Robert **CORCORAN**

Dr. Mark **DE ROSCH**

Lorrie **FERRARO**

Mike **KEAVANY**

Dr. Neil **SCHAUER**

INSPIRATION STRENGTHENS LEADERSHIP TEAM



Inspiration Biopharmaceuticals has expanded its executive team as the biopharmaceutical company moves toward commercialization of products in late-stage development for hemophilia.



Robert Corcoran has been appointed senior VP, quality. Mr. Corcoran was most recently VP of quality at Aegerion Pharmaceuticals. He received an M.S. from the University of Massachusetts Lowell.



Mark De Rosch, Ph.D., has joined Inspiration as VP, regulatory affairs. Dr. De Rosch was previously senior director of global regulatory strategy at Vertex Pharmaceuticals. He earned a Ph.D. from the University of California, San Diego.



Lorrie Ferraro has been named VP, human resources. Ms. Ferraro joins Inspiration from Parexel International, where she served as VP, human resources.

Mike Keavany has been named VP of commer-

cial operations, North America. Mr. Keavany previously served as VP of sales and operations at CSL Behring.

Neil Schauer, Ph.D., has been appointed VP, process sciences. Dr. Schauer was previously senior director, process development, global biologics research and development, at Hospira. He received a Ph.D. from Virginia Polytechnic Institute and State University.

Dr. Thorsten **EICKENHORST**

EMD SERONO TAPS FORMER BIOGEN IDEC VP AS MEDICAL CHIEF



EMD Serono, the U.S. biopharmaceutical subsidiary of German pharma and chemical group Merck KGaA, has named Thorsten Eickenhorst, M.D., Ph.D., as U.S. chief medical officer and head of U.S. development. Dr. Eickenhorst's responsibilities include working with the regulatory, medical, and development teams locally and globally to enhance EMD Serono's clinical presence in the United States.

Dr. Eickenhorst previously served as VP of clinical development and medical research at Biogen Idec. He received an M.D. and a Ph.D. from Freie Universität Berlin, a postgraduate studies in management (PSM) from Universitätsseminar der Wirtschaft in Germany, and an MBA from the University of Toronto.

Dr. Darlene **HORTON**

NILE THERAPEUTICS APPOINTS CEO



Nile Therapeutics, a biopharmaceutical company that develops novel therapeutics for heart failure patients, has promoted Darlene Horton, M.D., to president and CEO. Dr. Horton joined Nile in June 2012 as chief medical officer.

Dr. John **KAMERUD**

EMD MILLIPORE ADDS SCIENTIFIC DIRECTOR



EMD Millipore, the U.S.-based life-sciences division of Germany's Merck KGaA, has appointed John Kamerud, Ph.D., principal scientific director for discovery and development solutions in the company's bioscience business unit based at EMD Millipore's St. Charles, Mo., facility. Dr. Kamerud's responsibilities include driving EMD Millipore's new technology and services strategy, and leading client development programs with a focus on expanding the large molecule bioanalysis capabilities and customer base.

David MEEK**ENDOCYTE ADDS COMMERCIAL CHIEF**

Endocyte, a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, has appointed David Meek chief commercial officer. Mr. Meek is responsible for the development of Endocyte's commercial team and the company's overall commercial strategy and execution.

He joins Endocyte after more than seven years at Novartis Pharma AG, where he was most recently the head of northern and central Europe oncology.

Andrew ROBBINS**ARRAY BIOPHARMA SELECTS COMMERCIAL OPERATIONS VP**

Array BioPharma, a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases, has appointed Andrew Robbins senior VP of commercial operations. Mr. Robbins' responsibilities include working with Array's research and development teams to refine the company's strategy, prioritizing portfolio investments and supporting corporate collaborations with Array's strategic partners.

Mr. Robbins was most recently general manager/VP of Hospira's U.S. alternate site business unit. He received an MBA from the Kellogg School of Management, Northwestern University.

► SPECIALTY POOL**Dr. James CASSELLA****Dr. Edwin KAMEMOTO****Darl MORELAND****EXECUTIVE PROMOTIONS AT ALEXZA PHARMACEUTICALS**

Alexza Pharmaceuticals has announced four management promotions.

James Cassella, Ph.D., has been promoted to executive VP, research and development, and chief scientific officer. Dr. Cassella joined Alexza in 2004 as senior VP, re-



search and development. He received a Ph.D. in physiological psychology from Dartmouth College.

Edwin Kamemoto, Ph.D., has been elevated to VP, regulatory affairs, from executive director, regulatory affairs. He received a Ph.D. in biochemistry from the University of California, Los Angeles.



Darl Moreland has been promoted to senior VP, quality. Mr. Moreland joined Alexza in 2010 as VP, quality.

► EMERGING POOL**Dr. Glenn NEDWIN****CAISSON BIOTECH NAMES CHIEF EXECUTIVE**

Caisson Biotech, a biopharmaceutical company with the patented drug delivery technology HEPTune, has appointed Glenn Nedwin, Ph.D., CEO and president.

Dr. Nedwin has more than 30 years of experience in the pharmaceutical and biotechnology industries, having held positions such as president of Novozymes and executive VP of the Genencor Division of Danisco recently acquired by DuPont.

He received a master's degree in the management of technology from Massachusetts Institute of Technology Sloan School of Management and a Ph.D. in biochemistry from the University of California, Riverside.

Dr. Guillaume PFEFER**KALA SELECTS FORMER SANOFI PASTEUR EXECUTIVE AS CEO**

Kala Pharmaceuticals, a developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat a wide range of debilitating diseases, has named Guillaume Pfefer, Ph.D., president and CEO.

Dr. Pfefer joins Kala after nine years with Sanofi Pasteur, where he most recently served as general manager of Sanofi Pasteur Mexico.

He holds a master's degree in chemical engineering from the National School for Chemical Engineering in Nancy, France; a Ph.D. in materials science from Centre National de la Recherche Scientifique (CNRS) in France; and an MBA from the Wharton School at the University of Pennsylvania.

► ASSOCIATION POOL**Dr. Peter ALTERMAN****GOVERNMENT INFORMATION SECURITY VETERAN JOINS SAFE-BIOPHARMA**

Peter Alterman, Ph.D., has been named chief operating officer of Safe-BioPharma Association, the strategic, nonprofit collaboration responsible for the global SAFE-BioPharma digital identity and digital signature standard used in the life-sciences and healthcare sectors.

In addition to responsibilities for a variety of association management functions, Dr. Alterman serves as Safe-BioPharma's primary liaison with the U.S. FDA and other global regulatory authorities and represent the association's interests on global standards and policy bodies. He recently retired after 33 years of U.S. government service where he most recently served as senior advisor to the National Program Office of the National Strategy for Trusted Identities in Cyberspace (NSTIC), NIST.

► CONSULTING POOL**Alan CROWTHER****ALLIANCE LIFE SCIENCES MERGES WITH ADJILITY CONSULTING**

Management and technology consultancy Alliance Life Sciences Consulting Group (ALSCG) has agreed to merge with Adjility Consulting, a firm specializing in management consulting and analytic solutions for clinical operations and the global market access, pricing, and reimbursement space. As part of the merger, Adjility CEO Alan Crowther has become CEO of ALSCG. Mr. Crowther succeeds Jerry Benison, who was serving as acting CEO of ALSCG and has returned to his duties on the ALSCG board of directors.

Gary JACOBS**PWC BOLSTERS HEALTH INDUSTRIES ADVISORY PRACTICE**

Gary Jacobs has joined PwC US health industries advisory practice as a managing director based in Washington, D.C. Mr. Jacobs is leading a PwC initiative to help healthcare providers, health insurance companies, and pharmaceutical companies develop strategies for Medicare, Medi-

caid, shared-savings programs, state dual integration efforts, and managed long-term care models.

Mr. Jacobs was previously senior VP of corporate development and government relations at Universal American. He has a master's degree in public administration from American University.

Dr. David MITCHELL

CLINPHARM CONSULTING STRENGTHENS DRUG DEVELOPMENT EXPERTISE



David Mitchell, Ph.D., has joined ClinPharm Consulting as VP and executive consultant. Dr. Mitchell has directed clinical pharmacology programs at companies such as Pfizer and Procter & Gamble Pharmaceuticals during his 20-year career, and currently serves as president of the American Association of Pharmaceutical Scientists.

Hazel SEABROOK

HURON ANNOUNCES HEALTHCARE PRACTICE PROMOTION



Huron Consulting Group, a provider of business consulting services, has appointed Hazel Seabrook to lead the clinical operations solution within the company's Huron Healthcare practice.

Ms. Seabrook joined Huron Healthcare in 2007 as a managing director. She is a registered nurse and holds an MBA from Webster University.

CRO POOL

**Chris CRAMER
Sally DU TOIT**

QUANTICATE BOLSTERS EXECUTIVE TEAM



Global data-focused clinical research organization (CRO) Quanticate has added two VPs to its management roster. Sally Du Toit has joined Quanticate as VP of pharmacovigilance. Ms. Du Toit was previously director of pharmacovigilance at Aptiv Solutions.



Chris Cramer has been appointed VP of clinical data management. Ms. Cramer was most recently with PharmaNet, where she was responsible for European data management operations.

Dr. Louis RENZETTI



FORMER ROCHE VP JOINS PPD Pharmaceutical Product Development (PPD) has appointed Louis Renzetti, Ph.D., VP of strategic laboratory operations as the CRO continues im-

plementing strategies to integrate its laboratory and Phase I services with Phase II-IV services. Dr. Renzetti was previously VP and global head of Roche's RNA therapeutics division. He received a doctorate in physiology from Temple University School of Medicine.

SERVICE POOL

Catherine (Cathy) BALIN

NEW VP AT BENCH INTERNATIONAL



Bench International, a global executive recruiting and consulting firm serving the life-sciences industry, has appointed Catherine (Cathy) Balin a senior VP responsible for leading

Bench's retained executive search and strategic human resources consulting activities. Ms. Balin rejoins Bench after most recently serving as a VP for EXTTI. She holds a graduate certificate from the Joint International Executive Management Program of Harvard University and the University of Western Ontario, Canada.

Ethan BYLER

BHI EXPANDS STAFF



BioHealth Innovation (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, has named Ethan Byler director of innovation programs. Mr. Byler most recently served as the manager of engineering for global development at the American Society of Mechanical Engineers. He received a master's degree from the Fels Institute of Government at the University of Pennsylvania.

Mr. Byler most recently served as the manager of engineering for global development at the American Society of Mechanical Engineers. He received a master's degree from the Fels Institute of Government at the University of Pennsylvania.

Jim PANTALEO

NEW MARKETING VP AT MEDISCRIPTS



MediScripts, a point-of-prescription advertising medium, has named Jim Pantaleo as executive VP, sales and marketing. Mr. Pantaleo previously served as VP of sales and marketing for Haymarket Media.

TECHNOLOGY POOL

Adi ASAVAID

IMPACTRX APPOINTS SOLUTIONS DESIGN VP

ImpactRx, a Symphony Health Solutions company



and provider of consultative and analytically based commercial effectiveness solutions to the healthcare industry, has named Adi Asavaid senior VP, solutions design and implementation.

Mr. Asavaid is leading the design and development of innovative solutions fueled by the integration of the foundational data assets of ImpactRx and Source Healthcare Analytics to deliver breakthrough insight to clients.

Mr. Asavaid was VP for retail solutions at Opera Solutions. He earned an MBA from the Kellogg School of Management, Northwestern University.

John BLAKELEY

FORMER ERT COMMERCIAL CHIEF JOINS GREENPHIRE



John Blakeley has joined clinical payment technologies provider Greenphire as chief commercial officer. Mr. Blakeley is responsible for leading Greenphire's global marketing and

sales strategy as the company continues to extend the adoption of its clinical payment technology platforms, the ClinCard System and the eClinicalGPS, to the pharmaceutical, medical device, and contract research markets.

Before joining Greenphire, Mr. Blakeley spent 10 years in senior management and executive roles at ERT, most recently as chief commercial officer.

Mark MAIETTA

CRF HEALTH ADDS GLOBAL BUSINESS DEVELOPMENT VP



CRF Health, a global provider of eCOA (electronic clinical outcome assessments) solutions for the life-sciences industry, has named Mark Maietta senior VP for global business development. Mr.

Maietta was previously director of global business development at OptumInsight. He received an MBA from Binghamton University.

Douglas THIEDE

NEW BUSINESS DEVELOPMENT VP AT QFORMA



Qforma, a provider of healthcare data analytics and predictive modeling technology, has named Douglas Thiede VP, business development. Mr. Thiede joins Qforma from Gerson Lehrman Group


(GLG), where he was instrumental in driving growth in their life-sciences business. **PV**

USE YOUR QR CODE READER
OR GO TO
bit.ly/PV1012-TalentPool



2012 HBA Leadership Conference

November 7-9, 2012 • Orlando, Florida



WHERE LEADERSHIP PATHS
CONVERGE
ENLIGHTEN EMPOWER EVOLVE

Make plans to join us for a conference that only the HBA can deliver with top speakers, inspiring leadership stories, actionable skill development and opportunities to network with peers and senior women leaders from all sectors of healthcare.

We're pleased to introduce to you the three keynote speakers for the conference:



Pat Mitchell



Bonnie St. John



Noreen Fraser

Pat Mitchell, President and CEO of The Paley Center for Media

Bonnie St. John, Author and Olympic Athlete

Noreen Fraser, Founder of the Noreen Fraser Foundation

www.HBAnet.org



REQUIRED EXPERIENCE FOR HEALTHY CAREERS

▶ BIOTECHNOLOGY POOL

Guy CIPRIANI

NEW BUSINESS DEVELOPMENT VP AT ONCOTHYREON

Guy Cipriani has joined Oncothyreon as VP, business development, responsible for leading the biotech company's business development activities for its pipeline of small molecule and immunotherapy product candidates for cancer. Mr. Cipriani most recently served as chief business officer for Immune Design Corp. He received an MBA from the Kellogg School of Management at Northwestern University.

Andrea FERRENZ

Jane Shen YOUNG

CELLTEX THERAPEUTICS EXPANDS LABORATORY OPERATIONS

Celltex Therapeutics, a provider of regenerative medicine services, has named Andrea Ferrenz executive VP, legal counsel. Ms. Ferrenz has more than 15 years of experience in regulatory compliance and litigation, with expertise in food, drug and health law.

Ms. Ferrenz was most recently principal attorney at Emord & Associates. She received a J.D. from George Washington University Law School.

Jane Shen Young, M.D., Ph.D., has joined Celltex as manufacturing research scientist. Dr. Young was most recently associate research scientist at Pharmaceutical Product Development. She received a medical degree from Zhejiang University School of Medicine in China and a doctoral degree from Lund University, Faculty of Medicine, in Sweden.

Dr. James MOND

ADMA BIOLOGICS NAMES SCIENTIFIC CHIEF

ADMA Biologics, a late-stage biotechnology company focused on the development and commercialization of human plasma and plasma-derived therapeutics, has appointed James Mond, M.D., Ph.D., chief medical and scientific officer responsible for strategy and advancing the company's programs. Dr. Mond was most recently executive VP and chief scientific officer of Biosynexus. He received a M.D. and a Ph.D. from New York University Medical School.

▶ BIOPHARMACEUTICAL POOL

Caesar BELBEL

Dr. Hagop YOUSOUFIAN

ZIOPHARM ONCOLOGY REALIGNS MANAGEMENT

Ziopharm Oncology, a biopharmaceutical company focused on the development and commercialization of new cancer therapies, has unveiled a new executive leadership structure. Caesar Belbel, executive VP, chief legal officer, and secretary, has added responsibility for corporate and business development, while Hagop Youssoufian, M.D., in addition to his responsibilities as president of research and development and chief medical officer, has assumed oversight of all regulatory affairs and clinical operations.

David HAPPEL

DYNAVAX APPOINTS GLOBAL MARKETING VP

Dynavax Technologies, a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases, has named David Happel VP of global sales and marketing. Mr. Happel is responsible for directing the execution of Dynavax's commercialization strategy, market development, and sales and distribution, as well as overseeing the company's commercial organization. Mr. Happel was most recently VP, sales & marketing for proprietary products, at Dr. Reddy's Laboratories. He received an MBA in marketing from Indiana State University.

Dr. Michael HOLFINGER

AFFYMAX PROMOTES MANUFACTURING VP

Affymax has promoted Michael Holfinger, Ph.D., to VP, manufacturing and CMC development. Dr. Holfinger, who has more than two decades of experience in global manufacturing services for pharmaceutical and biotechnology companies, joined Affymax in 2006 as director, process development and manufacturing. He received a Ph.D. in chemical engineering from the University of Wisconsin-Madison.

Affymax is a biopharmaceutical company focused on discovering, developing, and delivering innovative therapies that improve the lives of patients with kidney disease and other serious, often life-threatening illnesses.

Dr. Zivile KATILIENE

Dr. Emmanuel KATSANIS

IMMUNOVATIVE THERAPIES ADDS TWO EXECUTIVES

Israeli biopharmaceutical company Immunovative Therapies has appointed Zivile Katiliene, Ph.D., as director of regulatory affairs and clinical operations, responsible for assuring compliance with FDA regulations and preparing and assuring the accuracy of regulatory submissions as well as the development of global clinical research operations.

Dr. Katiliene previously worked at the University of Colorado Cancer Center where her primary re-

sponsibility was to oversee management of all clinical research to assure compliance with federal regulations related to good clinical practices (GCP), including development, maintenance, and support of systems and business processes. She has a Ph.D. in chemistry and a graduate degree in clinical research management, both from Arizona State University.

Emmanuel Katsanis, M.D., has joined as chief medical officer, medical monitor, and chairman of the scientific advisory board. Dr. Katsanis' responsibilities include providing medical guidance, strategic advice, and oversight of Immunovative Therapies' worldwide clinical development programs, including selection of target indications, protocol design, and design of immunological monitoring endpoints. He is a board-certified pediatric hematologist/oncologist and professor of pediatrics, medicine, pathology, and immunobiology at the University of Arizona College of Medicine.

Dr. Adrian SENDEROWICZ

TOKAI PHARMACEUTICALS ADDS MEDICAL CHIEF

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, has named Adrian Senderowicz, M.D., chief medical officer and VP, medical development. Dr. Senderowicz was most recently senior medical director of oncology clinical development at AstraZeneca. He holds both an M.D. and an instructor of pharmacology degree from the School of Medicine at the Universidad de Buenos Aires in Argentina.

▶ SPECIALTY POOL

Dr. Stefan SCHWABE

SUPERNUS PHARMACEUTICALS APPOINTS MEDICAL CHIEF

Supernus Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, has named Stefan Schwabe M.D., Ph.D., executive VP of research and development and chief medical officer. Dr. Schwabe is responsible for all Supernus product development activities, including clinical, regulatory, and pharmaceutical sciences. He most recently served as chief operating officer at DemeRx.

▶ GENERIC POOL

Dinesh DUA

Dr. Bruce KUTINSKY

AKORN SELECTS CHIEF EXECUTIVE FOR INDIAN SUBSIDIARY

Niche generic pharmaceutical company Akorn has appointed Dinesh Dua CEO and managing director of its Indian subsidiary, Akorn India Pvt. Ltd. (AIPL). Mr. Dua was previously CEO of Nectar Life-sciences. He received a master's in business management from the Indian Institute of Management, Ahmedabad, India.

In other moves, Bruce Kutinsky, Pharm.D., has been promoted to chief operating officer of Akorn's U.S. operations, from president of the company's consumer health business. Mr. Kutinsky joined Akorn in late 2009 as senior VP of corporate strategy. He holds a doctorate of pharmacy from the University of Michigan.

▶ CONSULTING POOL

Mark MEEK

NEW PRESIDENT OF DECISION RESOURCES' BIOPHARMA UNIT

Decision Resources Group, a research and advisory firm focusing on healthcare insights, analysis, and consulting, has appointed Mark Meek president of the company's biopharma business unit. Mr. Meek is responsible for managing and expanding the biopharma unit, which includes Arlington Medical Resources, BioTrends Research Group, Decision Resources, and Manhattan Research. He was most recently CEO of Progressive Digital Media Group.

▶ CRO POOL

Shannon GORDON

THEOREM CLINICAL APPOINTS PROJECT MANAGEMENT VP

Full-service CRO Theorem Clinical Research has named Shannon Gordon VP of global project management, responsible for the oversight of activities such as quality deliverables, staff, project status, and budget oversight in more than 10 countries. Ms. Gordon was previously senior director, project delivery, with PRA International.

Leanne LARSON

PAREXEL CONSULTING STRENGTHENS OUTCOMES RESEARCH

Parexel Consulting, a business unit of Parexel International, has appointed Leanne Larson VP, evidence development. Ms. Larson's expertise in strategy, design, implementation, and analysis of patient registries and outcomes research programs will further support clients in meeting the needs of payers, regulators, physicians, and patients when making treatment decisions.

Ms. Larson has more than 25 years of experience in healthcare, featuring extensive work in pharmaceutical product development and marketing, and in healthcare technology and operational consulting. She received an MHA from Governors State University.

Manuela NIEWEL

MEDPACE STRENGTHENS ONCOLOGY EXPERTISE

Global full-service clinical research organization Medpace has appointed Manuela Niewel, M.D., Ph.D., a senior medical director in the area of oncology. Based in Munich, Dr. Niewel is charged with supporting Medpace's European growth with regard to oncology studies supporting global Medpace sponsors.


Dr. Niewel is a senior-level medical oncologist who was most recently a senior medical director oncology with PharmaNet in Germany. She received a medical degree and oncology specialist training from the University of Munich.

▶ SERVICE POOL

Jonathan SONG

C3I APPOINTS ASIA BUSINESS DEVELOPMENT EXECUTIVE

C3i, a provider of service desk support and business process outsourcing services for the life-sciences industry, has named Jonathan Song business development executive in Asia. Mr. Song is supporting C3i's strategy to expand its clinical and commercial solutions to pharmaceutical, biotechnology, and clinical research organizations in Asia.

Mr. Song has 20 years of pharmaceutical and healthcare experience in China and the USA, both on the industry and agency sides. He received a master's degree in management from Rensselaer Polytechnic Institute. 

Hard-copy and PDF Reprints

Reprints are a great way to showcase your press.

Hard-copy Reprints

Customized printed reproductions of your article. You can add your company logo or advertisement to increase its marketing value.

Eprints

Electronic version of a Reprint. Great for posting on your website or for e-mailing. Formatted as a pdf.

Call 215-321-8656 or e-mail mwalsh@pharmavoices.com to discuss your reprint needs with Marah Walsh.

